AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ICLR · NASDAQ · Medical - Diagnostics & Research

ICON (ICLR)

Runs outsourced clinical development programs for drug and medical-device makers worldwide.

$167.06

vs last close−0.05 (−0.03%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	2,055	2,066	2,090	2,120	2,030	2,041	2,001	2,017	2,043	2,113	2,034	2,063
Cost of revenue	1,449	1,446	1,471	1,494	1,439	1,442	1,443	1,456	1,587	1,632	1,556	1,675
Gross profit	606	621	619	627	591	599	559	562	456	481	478	389
	342	355	334	397	306	302	339	352	197	270	304	194
	185	196	177	194	205	151	198	205	197	180	201	194
General & administrative	0	0	0	0	0	0	0	0	0	0	201	0
Other expenses	156	159	156	202	101	151	141	147	0	90	104	0
Operating income	264	266	285	230	285	297	220	209	259	211	174	194
	−83	−79	−70	−60	−51	−48	−46	−48	−221	−51	−46	−102
Interest income	1	2	2	1	2	3	2	2	0	1	2	3
Interest expense	84	81	72	61	53	51	48	50	50	40	48	49
Other non-operating income	−1	−2	−2	−1	−2	28	−2	−2	171	11	−13	0
Income before tax	182	186	216	170	235	249	174	161	38	160	128	92
Income tax expense	18	−30	28	23	37	−11	20	−22	36	11	23	20
Net income from continuing operations	164	216	187	147	197	260	154	183	2	149	105	73
Net income	164	216	187	147	197	260	154	183	2	149	105	73
EPS, basic	$1.99	$2.63	$2.27	$1.78	$2.38	$3.18	$1.91	$2.31	$0.03	$1.95	$1.37	$0.94
EPS, diluted	$1.97	$2.60	$2.25	$1.76	$2.36	$3.16	$1.90	$2.30	$0.03	$1.93	$1.36	$0.94
Weighted average shares, basic	82	82	83	83	83	82	82	79	77	78	77	77
Weighted average shares, diluted	83	83	83	83	83	82	82	80	78	79	77	77
EBITDA	422	425	437	381	381	366	317	309	187	487	277	294
Depreciation & amortization	156	157	149	150	93	97	96	98	98	287	90	100
EBIT	266	267	287	231	288	269	221	211	88	200	187	194